Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Missing Authorization
Priority LOW 31CWE-862Published · Updated
Key facts
- Attack vector
- Adjacent network
- Privileges required
- None
- User interaction
- None
- Attack complexity
- Low
- Attack requirements
- None
- Impact type
- Security bypass
- Confidentiality · integrity · availability
- None · None · High
- Fix status
- No fix listed
Attack profile from CVSS 4.0 · CNA. Fix status from CNA. Impact type from CWE-862.
Summary
An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection.
Why it matters now
Exploitation None reported CISA SSVC · not in CISA KEV
EPSS 0.00348 28th percentileScored 2026-11-07
Fix No fix listed No fixed version in the sources yet
SSVC decision points
CISA ADP · SSVC 2.0.3
- Exploitation
- None
- Automatable
- No
- Technical impact
- Partial
The decision (Track, Attend, Act) also depends on your mission and well-being impact; see CISA's SSVC guide.
Affected products
| Vendor | Product | Affected versions | Fixed in | Status | Source |
|---|---|---|---|---|---|
| Apollo Pharmacy | Blood Glucose Monitoring System (Model No. APG-01 BT) | 0x0110_v1.1.0 | — | No fix listed | CNA |
- Blood Glucose Monitoring System (Model No. APG-01 BT) VendorApollo Pharmacy Affected 0x0110_v1.1.0 Fixed in — No fix listed CNA
Remediation
No fixed version listed by the sources yet.
Timeline
- 2026-10-02 Threatist record created from CVE-2026-52866
- 2026-10-03 Alias added: GHSA-47r7-422p-6w2p
References
More Apollo Pharmacy vulnerabilities
- TI-2026-36859 Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Cleartext Transmission of Sensitive Information CVSS 4.0HIGH 7.1
Sources
- CVE-2026-52866 · CVE Program
- CVE-2026-52866 · NVD
- FIRST EPSS
- GHSA-47r7-422p-6w2p · GitHub Advisory Database · CC BY 4.0
This product uses the NVD API but is not endorsed or certified by the NVD. Sources and licences